Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis

Tumori

Volumn 90, Issue 1, 2004, Pages 2-8

  Brader, Sharon ^a   Eccles, Suzanne A ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Invasion; Metastasis; Motility; Phosphoinositide 3 kinase

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANGIOGENESIS; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL FEATURE; CYTOSKELETON; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME REGULATION; EXTRACELLULAR MATRIX; GENE ACTIVATION; HUMAN; HYPOXIA; INFORMATION RETRIEVAL; MEDLINE; PHOSPHOINOSITIDE METABOLISM; REVIEW; TUMOR GROWTH; UPREGULATION;

EID: 2142759556     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000102     Document Type: Review

References (68)

1. Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathways in human cancer. Nature Cancer Rev, 2: 489-501, 2002.
2. Vazquez F, Sellers W: The PTEN tumour suppressor protein: an antagonist of phosphoinositide 3-kinase signalling. Biochem Biophys Acta, 1470: M21-35, 2000.
3. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW: PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet, 21: 99-102, 1999.
4. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA: The phosphatidylinositol 3'-kinase p85 alpha gene is an oncogene in human ovarian and colon tumours. Cancer Res, 61: 7426-7429, 2001.
5. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma X, Shelly SA, Jove R, Tsichlis PN, Nicosia SV, Cheng J, Q: AKT1/PKB kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol, 159: 431-437, 2001.
6. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer, 64: 280-285, 1995.
7. Ali IU, Schriml LM, Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumour suppressor with lipid phosphatase activity. J Natl Cancer Inst, 91: 1922-1932, 1999.
8. Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, Isonishi S, Yasuhara T, Yoshimura T, Ohtake Y, Ochiai K, Yokota J, Tanaka T: Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer, 85: 160-165, 2000.
9. Zhang L, Yang N, Katsaros D, Huang W, Park JW, Fracchioli S, Vezzani C, Rigault de la Longrais IA, Yao W, Rubin SC, Coukos G: The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res, 63: 4225-4231, 2003.
10. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY: PIK3CA as an oncogene in cervical cancer. Oncogene, 19: 2739-2744, 2000.
11. Phillips WA, St. Clair F, Munday AD, Thomas RJ, Mitchell CA: Increased levels of phosphoinositol 3-Kinase activity in colorectal tumours. Cancer, 83: 41-47, 1998.
12. Guanti G, Resta N, Simone C, Cariola F, Demma I, Fiorente P, Gentile M: Involvement of PTEN mutations in the genetic pathways of colorectal carcogenesis. Hum Mol Genet, 9: 283-287, 2000.
13. Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, Provencio M, Espana P, Bonilla F: Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treatment, 57: 237-243, 1999.
14. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, Roth RA: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem, 274: 21528-21532, 1999.
15. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR: Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci, 93: 3636-3641, 1996.
16. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res, 57: 4183-4186, 1997.
17. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH: PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res, 57: 4187-4190, 1997.
18. Celebi JT, Shendrik I, Silver DN, Peacocke M: Identification of PTEN mutations in metastatic melanoma specimens. J Med Genet, 37: 653-657, 2000.
19. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C: Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol, 157: 1123-1128, 2000.
20. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL: Inactivation of the tumour suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci, 95: 5246-5250, 1998.
21. Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ, Ritz J, Freedman A, Stiles C, Eng C: PTEN is inversely correlated with the cell survival factor akt/pkb and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet, 8: 185-193, 1999.
22. Nakahara Y, Nagai H, Kinoshita T, Uchida T, Hatano S, Murate T, Saito H: Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma. Leukaemia, 12: 1277-1280, 1998.
23. Staal SP: Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Nat Acad Sci, 84: 5034-5037, 1987.
24. Kobayashi M, Iwamatsu A, Shinohara-Kanda A, Ihara S, Fukui Y: Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. Oncogene, 22: 1294-1301, 2003.
25. Forgacs E, Biesterveld EJ, Sekido Y, Fong K, Muneer S, Wistuba II, Milchgrub S, Brezinschek R, Virmani A, Gazdar AF, Minna JD: Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene, 17: 1557-1565, 1998.
26. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ: Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol, 21: 2203-12, 2001.
27. Scheid MP, Woodgett JR: Phosphatidylinositol 3' kinase signalling in mammary tumorigenesis. J Mammary Gland Biol Neoplasia, 6: 83-99, 2001.
28. Mayo LD, Donner DB: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA, 98: 11598-11603, 2001.
29. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a PI3 kinase/Akt signalling pathway in Ha-ras transformed cells through a HIF-1 transcriptional element. Blood, 90: 3322-3331, 1997.
30. Koul D, Shen R, Garyali A, Ke LD, Liu TJ, Yung WK: MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer. Int J Oncol, 21: 469-475, 2002.
31. Wang D, Huang H-J, Kazlauskas A, Cavanee WK: Induction of vascular endothelial growth factor expression in endothelial cells by platelet derived growth factor through the activation of PI3-kinase. Cancer Res, 59: 1464-1472, 1999.
32. O-charoenrat P, Rhys-Evans P, Modjtahedi H, and Eccles SA. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 18: 155-161, 2000.
33. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C: Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res, 61: 5911-5918, 2001.
34. Yu Y, Hulmes JD, Herley MT, Whitney RG, Crabb JW, Sato JD: Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3'-kinase binding. Biochem J, 358: 465-472, 2001.
35. Thakker GD, Hajjar DP, Muller WA, Rosengart TK: The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem, 274: 10002-10007, 1999.
36. Qi JH, Claesson-Welsh L: VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. Exp Cell Res, 263: 173-182, 2001.
37. Fujikawa K, de Aos Scherpenseel I, Jain SK, Presman E, Christensen RA, Varticovski L: Role of PI 3-kinase in angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells. Exp Cell Res, 253: 663-672, 1999.
38. Nakashio A, Fujita N, Tsuruo T: Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int J Cancer, 98: 36-41, 2002.
39. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 399: 601-605, 1999.
40. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Naure Med, 8: 128-135, 2002.
41. Lauffernburger DA, Horwitz AH: Cell migration: a physically integrated molecular process. Cell, 84: 359-369, 1996.
42. Hood J, Cheresh D: Role of integrins in cell invasion and migration. Nature Cancer Reviews, 2: 91-100, 2002.
43. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Brocker EB, Friedl P: Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol, 160: 267-277, 2003.
44. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC: Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-1 depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase. Cancer Res, 61: 1367-1374, 2001.
45. Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS, Hudson LG: Phosphatidylinositol 3-kinase activity in epithelial growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res, 61: 1855-1861, 2001.
46. Zhang D, Brodt P: Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signalling. Oncogene, 22: 974-982, 2003.
47. Adelsman M, McCarthy J, Shimizu Y: Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence 9 on phosphoinositide 3-OH kinase. Mol Biol Cell, 10: 2861-2878, 1999.
48. Gambaletta D, Marchetti A, Benedetti L, Mercurio A, Sacchi A, Falcioni R: Cooperative signalling between alpha6beta4 integrin and erbB-2 receptor is required to promote phosphatidylinositol 3-kinase-dependent invasion. J Biol Chem, 275: 10604-10610, 2000.
49. Persad S, Attwell S, Virginia G, Delcommenne M, Troussard A, Sanghera J, Dedhar S: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA, 97: 3201-3212, 2000.
50. Ahlen K, Berg A, Stiger F, Tengholm A, Siegbahn A, Gylfe E, Reed RK, Rubin K: Cell interactions with collagen matrices in vivo and in vitro depend on phosphatidylinositol 3-kinase and free cytoplasmic calcium. Cell Adhes Commun, 5: 461-473, 1998.
51. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada K: Inhibition of cell migration, spreading, and focal adhesions by tumour suppressor PTEN. Science, 280: 1614-1617, 1998.
52. Liliental J, Moon SY, Lesche R, Mamillapalli R, Li D, Zheng Y, Sun H, Wu H: Genetic deletion of the PTEN tumour suppressor gene promotes cell motility by activation of Rac1 and cdc42 GTPases. Curr Biol, 10: 401-404, 2000.
53. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW: Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'kinase and phospholipase C-dependent mechanism. Cancer Res, 59: 5475-5478, 1999.
54. Fledner JC, Brandt BH: Cancer cell motility - one the road from c-erbB-2 receptor steered signaling to actin reorganization. Exp Cell Res, 272: 93-108, 2002.
55. Jimenez C, Portela RA, Mellado M, Rodriguez-Frade JM, Collard J, Serrano A, Martinez AC, Avila J, Carrera AC: Role of PI3K regulatory subunit in the control of actin organization and cell migration. J Cell Biol, 151: 249-261, 2000.
56. Woscholski R, Kodaki T, McKinnon M, Waterfield MD, Parker PJ: A comparison of demethoxyviridin and wortmannin as inhibitors of phosphatidylinositol 3-kinase. FEBS Letters 342: 109-114, 1994.
57. Vlahos CJ, Matter WF, Hui KY, Brown RF: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyrN - 4-one (LY294002). J Biol Chem, 269: 5241-5248, 1994.
58. Cross MJ, Stewart A, Hodgkin MN, Kerr DJ, Wakelam MJ: Wortmannin and its structural homologue demethoxyviridin inhibit phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatylinositol 3-kinase. J Biol Chem, 270: 25352-25355, 1995.
59. Cross MJ, Hodgkin MN, Plumb JA, Brunton VG, Stewart A, MacAully G, Hill R, Kerr DJ, Workman P, Wakelam MJ: Inhibition of phospholipid signalling and proliferation of Swiss 3T3 cells by the wortmannin analogue demethoxyviridin. Biochim Biophys Acta, 1362: 29-38, 1997.
60. Davis SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J, 351: 95-105, 2000.
61. Hu L, Zaloudek C, Mills GB, Gray J, Jaffee RB: In vivo and in vitro ovarian carcinoma growth inhibition by phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res, 6: 880-886, 2000.
62. Semba S, Itoh N, Ito M, Harada M, Yamakawa M: The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenylchromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells. Clin Cancer Res, 8: 1957-1963, 2002.
63. Bondar V, Sweeny-Gotsch B, Andreeff M, Mills G, McConkey D: Inhibition of the phosphatidylinositol 3'-kinase-Akt pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Molec Cancer Therapeutics, 1: 989-997, 2002.
64. Boehle AS, Kurdow R, Boenicke L, Schniewind B, Feandrich F, Dohrmann P, Kalthoff H: Wortmannin inhibits growth of human non-small cell lung cancer in vitro and in vivo. Langenbecks Arch Surg, 387: 234-239, 2002.
65. Kip A, West S, Sianna Castillo S, Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Res Updates, 5: 234-248, 2002.
66. Hayakaa M, Kaizawa H, Kawaguchi KI, Matsuda K, Ishikawa N, Koizumi T, Yamanao M, Ohta M: Therapeutic morpholino-subsituted compounds. US patent, 6, 403,588 B 1, 2002.
67. Robertson AJ, Jackson S, Kenche V, Yaip C, Parbaharan H, Thompson P: Preparation and formulation of morpholino-subsituted heterocycles as phosphoinositide 3-kinase inhibitors for therapeutic use. International patent application, WO 0153266 A1: 2001.
68. Sadhu C, Dick K, Treiberg J, Sowell CG, Kesicki EA, Oliver A: Quinazolinone derivatives as inhibitors of human phosphatidylinositol 3-kinase delta. International patent application. WO 0181346 A2: 2001.